Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Aldosterone receptor antagonists: current perspectives and therapies.

Guichard JL, Clark D 3rd, Calhoun DA, Ahmed MI.

Vasc Health Risk Manag. 2013;9:321-31. doi: 10.2147/VHRM.S33759. Review.

2.

Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.

Whaley-Connell A, Johnson MS, Sowers JR.

Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):401-9. doi: 10.1016/j.pcad.2009.12.004. Review.

3.

Aldosterone and mineralocorticoid receptors in the cardiovascular system.

Funder JW.

Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):393-400. doi: 10.1016/j.pcad.2009.12.003. Review.

PMID:
20226957
4.

A mechanism for mineralocortcoid participation in renal disease and heart failure.

Re RN.

J Am Soc Hypertens. 2015 Aug;9(8):586-91. doi: 10.1016/j.jash.2015.05.002. Review.

PMID:
26101172
5.

Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.

McMahon EG.

Curr Opin Pharmacol. 2001 Apr;1(2):190-6. Review.

PMID:
11714095
6.

The Role of Aldosterone in Obesity-Related Hypertension.

Kawarazaki W, Fujita T.

Am J Hypertens. 2016 Apr;29(4):415-23. doi: 10.1093/ajh/hpw003. Review.

PMID:
26927805
7.

The ubiquitous mineralocorticoid receptor: clinical implications.

Hawkins UA, Gomez-Sanchez EP, Gomez-Sanchez CM, Gomez-Sanchez CE.

Curr Hypertens Rep. 2012 Dec;14(6):573-80. doi: 10.1007/s11906-012-0297-0. Review.

8.

Mineralocorticoid antagonism and cardiac hypertrophy.

Nagata K.

Curr Hypertens Rep. 2008 Jun;10(3):216-21. Review.

PMID:
18765093
9.

Hypertension: renin-angiotensin-aldosterone system alterations.

Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH.

Circ Res. 2015 Mar 13;116(6):960-75. doi: 10.1161/CIRCRESAHA.116.303587. Review.

10.

Aldosterone target organ protection by eplerenone.

Rudolph AE, Rocha R, McMahon EG.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):229-38. Review.

PMID:
15134822
11.

Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.

Luther JM, Luo P, Wang Z, Cohen SE, Kim HS, Fogo AB, Brown NJ.

Kidney Int. 2012 Sep;82(6):643-51. doi: 10.1038/ki.2012.170.

12.

Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma.

Amar L, Lorthioir A, Azizi M, Plouin PF.

Eur J Endocrinol. 2015 Mar;172(3):R125-9. doi: 10.1530/EJE-14-0585. Review.

13.

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.

Nappi JM, Sieg A.

Vasc Health Risk Manag. 2011;7:353-63. doi: 10.2147/VHRM.S13779. Review.

14.

This is not Dr. Conn's aldosterone anymore.

Brown NJ.

Trans Am Clin Climatol Assoc. 2011;122:229-43. Review.

15.

Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.

Hu X, Li S, McMahon EG, Lala DS, Rudolph AE.

Mini Rev Med Chem. 2005 Aug;5(8):709-18. Review.

PMID:
16101407
16.
17.

[Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].

Derer W, Dechend R, Müller DN.

MMW Fortschr Med. 2010 Feb 11;152(6):48-9. Review. German. No abstract available.

PMID:
20302183
18.

Role of mineralocorticoid receptor antagonists in cardiovascular disease.

Ferrario CM, Schiffrin EL.

Circ Res. 2015 Jan 2;116(1):206-13. doi: 10.1161/CIRCRESAHA.116.302706. Review.

19.

Vascular actions of aldosterone.

Briet M, Schiffrin EL.

J Vasc Res. 2013;50(2):89-99. doi: 10.1159/000345243. Review.

20.
Items per page

Supplemental Content

Support Center